ONCT Insider Trading
Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 11.20%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Oncternal Therapeutics Insider Trading History Chart
This chart shows the insider buying and selling history at Oncternal Therapeutics by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Oncternal Therapeutics Share Price & Price History
Current Price: $0.53
Price Change: +0.30 (1.20%)
As of 04/29/2025 01:00 AM ET
Oncternal Therapeutics Insider Trading History
SEC Filings (Institutional Ownership Changes) for Oncternal Therapeutics (NASDAQ:ONCT)
16.05% of Oncternal Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.
Institutional Buying and Selling by Quarter
This chart shows the instiutional buying and selling at ONCT by year and by quarter.
Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
Oncternal Therapeutics Institutional Trading History
Data available starting January 2016
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.
Read More on Oncternal Therapeutics
Volume
N/A
Average Volume
93,917 shs
Market Capitalization
$1.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.18
Who are the company insiders with the largest holdings of Oncternal Therapeutics?